Heron Therapeutics, Inc. (HRTX)

NASDAQ: HRTX · IEX Real-Time Price · USD
8.32 -0.39 (-4.43%)
Jan 18, 2022 3:08 PM EST - Market open
Market Cap847.59M
Revenue (ttm)86.30M
Net Income (ttm)-228.32M
Shares Out101.94M
EPS (ttm)-2.39
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,053,403
Open8.48
Previous Close8.70
Day's Range8.18 - 8.67
52-Week Range8.09 - 20.45
Beta1.34
AnalystsStrong Buy
Price Target31.50 (+278.8%)
Earnings DateNov 3, 2021

About HRTX

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycli...

IndustryBiotechnology
IPO DateAug 26, 1987
CEOBarry Quart
Employees223
Stock ExchangeNASDAQ
Ticker SymbolHRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is 31.50, which is an increase of 278.83% from the latest price.

Price Target
$31.50
(278.83% upside)
Analyst Consensus: Strong Buy

News

Heron's (HRTX) Zynrelef Gets FDA Nod for Label Expansion

The FDA grants label expansion to Heron???s (HRTX) Zynrelef for pain relief after small to medium abdominal surgeries, lower extremity total joint replacements, and foot and ankle surgeries in adults.

1 month ago - Zacks Investment Research

Why Heron Therapeutics Shares Rose Nearly 15% This Week

The company got approval for an expanded use for its post-surgery pain therapy.

1 month ago - The Motley Fool

FDA Approves Indication Expansion For Heron Therapeutics' Post-Op Pain Med

The FDA has approved Heron Therapeutics Inc's (NASDAQ: HRTX) supplemental application for Zynrelef (bupivacaine and meloxicam) extended-release solution to expand the indication.  Zynrelef is now indica...

1 month ago - Benzinga

2 Short-Squeeze Candidates That Could Go Parabolic Soon

Cortexyme and Heron Therapeutics are two of the most heavily shorted biopharma stocks right now.

Other symbols:CRTX
1 month ago - The Motley Fool

Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF®

SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

1 month ago - PRNewsWire

Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...

2 months ago - PRNewsWire

Heron Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...

2 months ago - PRNewsWire

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 15.00% and -7.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights ...

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

2 months ago - PRNewsWire

Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021

SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...

2 months ago - PRNewsWire

Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?

These once-promising biotech stocks are trading at a fraction of their all-time highs right now.

Other symbols:BLUE
3 months ago - The Motley Fool

Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Ind...

SAN DIEGO, Oct. 4, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

3 months ago - PRNewsWire

Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

SAN DIEGO, Sept. 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatme...

3 months ago - PRNewsWire

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -5.08% and -21.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent...

SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

5 months ago - PRNewsWire

Will Heron Therapeutics (HRTX) Report Negative Q2 Earnings? What You Should Know

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNR...

SAN DIEGO, July 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...

5 months ago - PRNewsWire

Heron Therapeutics' Zynrelef Shows Reduction In Post-Op Pain, Opioid Use Compared To Bupivacaine In Old-Aged Patients

Heron Therapeutics Inc (NASDAQ: HRTX) has announced the online publication of a new analysis from the Phase 3 EPOCH 1 and EPOCH 2 studies evaluating Zynrelef (bupivacaine and meloxicam) in adults aged 6...

5 months ago - Benzinga

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients...

SAN DIEGO, July 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...

5 months ago - PRNewsWire

Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™

SAN DIEGO, July 6, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

6 months ago - PRNewsWire

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative...

SAN DIEGO, July 1, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

6 months ago - PRNewsWire

Under Biden's Budget, These 2 Little-Known Biotechs Could Help End the Opioid Crisis

The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.

Other symbols:COLL
7 months ago - The Motley Fool

Heron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference

SAN DIEGO, May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

7 months ago - PRNewsWire

Trading Penny Stocks? 3 Biotech Stocks To Watch Before June 2021

Current & former penny stocks trading higher after surge of interest in biotech industry. The post Trading Penny Stocks?

Other symbols:GTBPPIRS
7 months ago - PennyStocks

Heron Therapeutics Announces $150 Million Convertible Debt Financing

SAN DIEGO, May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron") today announced that it has sold $150 million of senior unsecured convertible promissory notes (the "Notes") in ...

7 months ago - PRNewsWire